Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers

Journal of Clinical Oncology

Volumn 24, Issue 11, 2006, Pages 1656-1664

  Oh, Daniel S ^a   Troester, Melissa A ^a   Usary, Jerry ^a   Hu, Zhiyuan ^a   He, Xiaping ^a   Fan, Cheng ^a   Wu, Junyuan ^a   Carey, Lisa A ^a   Perou, Charles M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR GATA 3;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UNINDEXED SEQUENCE; BREAST TUMOR; CLASSIFICATION; DNA MICROARRAY; GENETICS; METHODOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 33645820586     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.2755     Document Type: Article

References (42)

1. Osborne CK, Yochmowitz MG, Knight WA III, et al: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884-2888, 1980
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
3. Bardou VJ, Arpino G, Elledge RM, et al: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases, J Clin Oncol 21:1973-1979, 2003
4. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618, 1998
5. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
6. Osborne CK, Bardou V, Hopp TA, et al: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361, 2003
7. Shou J, Massarweh S, Osborne CK, et al: Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935, 2004
8. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
9. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423, 2003
10. Dai H, van't Veer L, Lamb J, et al: A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Proc Natl Acad Sci U S A 65:4059-4066, 2005
11. Jansen MP, Foekens JA, van Staveren IL, et al: Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23:732-740, 2005
12. Ma XJ, Wang Z, Ryan PD, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5:607-616, 2004
13. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
14. Troester MA, Hoadley KA, Sorlie T, et al: Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 64:4218-4226, 2004
15. Hu Z, Troester M, Perou CM: High reproducibility using sodium hydroxide-stripped long oligonucleotide DNA microarrays. Biotechniques 38:121-124, 2005
16. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98:5116-5121, 2001
17. Larsson O, Wahlestedt C, Timmons JA: Considerations when using the significance analysis of microarrays (SAM) algorithm. BMC Bioinformatics 6:129, 2005
18. Eisen MB, Spellman PT, Brown PO, et al: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:14863-14868, 1998
19. Usary J, Llaca V, Karaca G, et al: Mutation of GATA3 in human breast tumors. Oncogene 23: 7669-7678, 2004
20. Bair E, Tibshirani R: Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2:E108, 2004
21. Bullinger L, Dohner K, Bair E, et al: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350:1605-1616, 2004
22. Chang HY, Nuyten DS, Sneddon JB, et al: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 102:3738-3743, 2005
23. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
24. Benito M, Parker J, Du Q, et al: Adjustment of systematic microarray data biases. Bioinformatics 20:105-114, 2004
25. Altucci L, Addeo R, Cicatiello L, et al: 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12:2315-2324, 1996
26. Finlin BS, Gau CL, Murphy GA, et al: RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. J Biol Chem 276: 42259-42267, 2001
27. Ghosh MG, Thompson DA, Weigel RJ: PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer Res 60:6367-6375, 2000
28. Jakowlew SB, Breathnach R, Jeltsch JM, et al: Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res 12:2861-2878, 1984
29. Hosack DA, Dennis G Jr, Sherman BT, et al: Identifying biological themes within lists of genes with EASE. Genome Biol 4:R70, 2003
30. Gruvberger S, Ringner M, Chen Y, et al: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61:5979-5984, 2001
31. Hoch RV, Thompson DA, Baker RJ, et al: GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 84:122-128, 1999
32. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100:10393-10398, 2003
33. West M, Blanchette C, Dressman H, et al: Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 98:11462-11467, 2001
34. Perou CM, Jeffrey SS, van de Rijn M, et al: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 96:9212-9217, 1999
35. Whitfield ML, Sherlock G, Saldanha AJ, et al: Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13:1977-2000, 2002
36. Otte M, Zafrakas M, Riethdorf L, et al: MAGE-A gene expression pattern in primary breast cancer. Cancer Res 61:6682-6687, 2001
37. Kavalar R, Sarcevic B, Spagnoli GC, et al: Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: An immunohistochemical study. Virchows Arch 439:127-131, 2001
38. Srinivasula SM, Ahmad M, Ottilie S, et al: FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem 272:18542-18545, 1997
39. Abedini MR, Qiu Q, Yan X, et al: Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 23:6997-7004, 2004
40. Wang CY, Guttridge DC, Mayo MW, et al: NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19:5923-5929, 1999
41. Cheng Q, Lee HH, Li Y, et al: Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Oncogene 19:4936-4940, 2000
42. Paik S, Shak S, Tang G, et al: Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. Presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004 (abstr 24)